{
  "source": "PA-Notification-Palynziq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1248-8\nProgram Prior Authorization/Notification\nMedication Palynziq™ (pegvaliase-pqpz)\nP&T Approval Date 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nPalynziq is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine\nconcentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine\nconcentrations greater than 600 micromol/L on existing management.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Palynziq will be approved based on all of the following criteria:\na. Diagnosis of phenylketonuria (PKU)\n-AND-\nb. Patient has a blood phenylalanine concentration greater than 600 micromol/L\n-AND-\nc. Patient is actively on a phenylalanine-restricted diet\n-AND-\nd. Patient is not receiving Palynziq in combination with sapropterin dihydrochloride\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Palynziq will be approved based on all of the following criteria:\na. Documentation of positive clinical response (e.g., blood phenylalanine concentration less\nthan 600 micromol/L, 20% reduction in blood phenylalanine concentration from pre-\ntreatment baseline)\n-AND-\nb. Patient is actively on a phenylalanine-restricted diet\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nc. Patient is not receiving Palynziq in combination with sapropterin dihydrochloride\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or t",
    "tial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity and supply limits may also be in place.\n4. References:\n1. Palynziq [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.\n2. Vockley et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline.\nAmerican College of Medical Genetics and Genomics Practice Guidelines. Genetics in Medicine\n2014;16 (2):188-200.\nProgram Prior Authorization/Notification - Palynziq (pegvaliase-pqpz)\nChange Control\n7/2018 New program\n7/2019 Annual review with no change to coverage criteria.\n7/2020 Annual review with no change to coverage criteria.\n7/2021 Annual review with no change to coverage criteria. Reference updated.\n7/2022 Annual review with no change to coverage criteria. Removed Brand name\nKuvan. Added state mandate disclaimer.\n7/2023 Annual review with no change to coverage criteria.\n7/2024 Annual review. Simplified reauthorization criteria to standard\ndocumentation of positive clinical response language.\n6/2025 Annual review with no change to coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}